Every Form 4 that Armata Pharmctcl (ARMP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ARMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ARMP filings page.
Armata Pharmaceuticals, Inc. reported that Chief Executive Officer Deborah Birx had 14,041 shares of common stock withheld on 2026-07-10 at $4.26 per share to satisfy income tax and withholding remittance obligations tied to the net settlement of restricted stock units. After this non-market, tax-withholding disposition, she directly holds 198,417 shares of Armata common stock.
Armata Pharmaceuticals director Daniel B. Gilmer received a grant of stock options for 51,280 shares of common stock. The options have an exercise price of $12.92 per share and expire on April 24, 2036.
According to the terms, one-third of the underlying shares vest on each of the first, second, and third anniversaries of the April 24, 2026 grant date, as long as Gilmer continues to provide service through each vesting date. After this grant, he holds 51,280 stock options directly.
Armata Pharmaceuticals, Inc. Chief Business Officer Pierre Kyme reported a small tax-related share disposition on common stock. On March 14, 2026, 1,030 shares were withheld at $10.54 per share to satisfy income tax and withholding obligations tied to restricted stock unit settlement. Following this transaction, Kyme directly holds 9,461 common shares.
Armata Pharmaceuticals’ CEO Deborah Birx reported a routine tax-withholding transaction involving company stock. On this Form 4, 4,919 shares of common stock were withheld by the company at $10.54 per share to cover income-tax obligations tied to the net settlement of restricted stock units. This was a tax-withholding disposition, not an open-market sale, and left Birx with direct ownership of 212,458 common shares.
Armata Pharmaceuticals director Robin Kramer received a grant of stock options, giving the right to buy 25,640 shares of common stock at an exercise price of $11.61 per share. These options vest in full on March 9, 2027, subject to continuous service, and expire on March 9, 2036. Following this grant, Kramer holds 25,640 stock options directly.
Armata Pharmaceuticals’ Chief Business Officer receives new stock option grant. On March 9, 2026, Pierre Kyme was granted stock options covering 183,142 shares of Armata Pharmaceuticals common stock at an exercise price of $11.6100 per share, expiring on March 9, 2036.
These options were awarded as a compensation grant and are held directly. According to the terms, 25% of the options vest on March 9 of each of 2027, 2028, 2029, and 2030, assuming continuous service through each vesting date. No open‑market purchases or sales were reported in this filing.
Armata Pharmaceuticals, Inc. reported that SVP, Finance, and Principal Financial Officer David Duane House received a grant of stock options to acquire 109,885 shares of Common Stock at an exercise price of $11.61 per share. These options were granted at no upfront cost and expire on March 9, 2036. According to the vesting terms, 25% of the options will vest on March 9 of each of 2027, 2028, 2029, and 2030, subject to his continuous service through each vesting date. Following this grant, he holds 109,885 stock options directly.
Armata Pharmaceuticals director Patti Joseph M received a grant of stock options representing rights to acquire 25,640 shares of common stock. The options have an exercise price of $11.61 per share and expire on March 9, 2036. According to the terms, the options will vest in full on March 9, 2027, provided she remains in continuous service through that date. Following this grant, she holds 25,640 stock options directly.
Armata Pharmaceuticals director Todd C. Peterson received a new stock option grant. On March 9, 2026, he was awarded options to purchase 25,640 shares of common stock at an exercise price of $11.6100 per share, expiring on March 9, 2036.
The options were granted as a compensation award and increased his directly held option position to 25,640 derivative securities. According to the terms, the award will vest in full on March 9, 2027, provided he remains in continuous service through that vesting date.
Armata Pharmaceuticals director Odysseas D. Kostas received a new stock option grant as equity compensation. On March 9, 2026, he was granted options covering 25,640 shares of Common Stock at an exercise price of $11.61 per share. The options have no cash cost at grant and expire on March 9, 2036. According to the disclosure, the entire grant will vest on March 9, 2027, provided he remains in continuous service through that date, and he now holds 25,640 options following this award.
Armata Pharmaceuticals, Inc. reported that Chief Executive Officer Deborah Birx received a grant of stock options for 421,226 shares of common stock on March 9, 2026. The options carry an exercise price of 11.6100 per share and fully represent her derivative holdings after this grant.
According to the terms, 25% of the options vest on March 9 of each of 2027, 2028, 2029, and 2030, in each case conditioned on her continuous service through the relevant vesting date.
Armata Pharmaceuticals director Sarah J. Schlesinger reported a grant of 25,640 stock options. These options give her the right to buy 25,640 shares of Armata common stock at an exercise price of $11.61 per share and are held as a direct derivative position.
The options were awarded on March 9, 2026 as a compensation-related grant with no cash paid by her at grant. They will vest in full on March 9, 2027, as long as she continues to serve through that date, and are scheduled to expire on March 9, 2036 if not exercised.
Armata Pharmaceuticals director Jules Haimovitz received a grant of stock options to acquire 25,640 shares of common stock. The options have an exercise price of 11.61 per share and expire on March 9, 2036. They will vest in full on March 9, 2027, subject to continuous service through that date. Following this award, Haimovitz holds 25,640 stock options directly.